Cargando…
Integrated flow-through purification for therapeutic monoclonal antibodies processing
An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to ha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825194/ https://www.ncbi.nlm.nih.gov/pubmed/29271693 http://dx.doi.org/10.1080/19420862.2017.1417717 |
_version_ | 1783302163076743168 |
---|---|
author | Ichihara, Takamitsu ITO, Takao Kurisu, Yasuhiko Galipeau, Kevin Gillespie, Christopher |
author_facet | Ichihara, Takamitsu ITO, Takao Kurisu, Yasuhiko Galipeau, Kevin Gillespie, Christopher |
author_sort | Ichihara, Takamitsu |
collection | PubMed |
description | An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to have excellent impurity clearance at high mAb loadings with overall mAb yield exceeding 80%. Robust removal of DNA and host cell protein was demonstrated by activated carbon and a new flow-through cation exchange resin exhibited excellent clearance of mAb aggregate with high monomer recoveries. A ten-fold improvement of mAb loading was achieved compared to a traditional cation exchange resin designed for bind and elute mode. High throughput 96-well plate screening was used for process optimization, focusing on mAb loading and solution conditions. Optimum operating windows for integrated flow-through purification are proposed based on performance characteristics. The combination of an all flow-through polishing process presents significant opportunities for improvements in facility utilization and process economics. |
format | Online Article Text |
id | pubmed-5825194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-58251942018-03-01 Integrated flow-through purification for therapeutic monoclonal antibodies processing Ichihara, Takamitsu ITO, Takao Kurisu, Yasuhiko Galipeau, Kevin Gillespie, Christopher MAbs Report An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to have excellent impurity clearance at high mAb loadings with overall mAb yield exceeding 80%. Robust removal of DNA and host cell protein was demonstrated by activated carbon and a new flow-through cation exchange resin exhibited excellent clearance of mAb aggregate with high monomer recoveries. A ten-fold improvement of mAb loading was achieved compared to a traditional cation exchange resin designed for bind and elute mode. High throughput 96-well plate screening was used for process optimization, focusing on mAb loading and solution conditions. Optimum operating windows for integrated flow-through purification are proposed based on performance characteristics. The combination of an all flow-through polishing process presents significant opportunities for improvements in facility utilization and process economics. Taylor & Francis 2018-01-16 /pmc/articles/PMC5825194/ /pubmed/29271693 http://dx.doi.org/10.1080/19420862.2017.1417717 Text en © 2018 The Author(s). Published with license by Taylor and Francis group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Report Ichihara, Takamitsu ITO, Takao Kurisu, Yasuhiko Galipeau, Kevin Gillespie, Christopher Integrated flow-through purification for therapeutic monoclonal antibodies processing |
title | Integrated flow-through purification for therapeutic monoclonal antibodies processing |
title_full | Integrated flow-through purification for therapeutic monoclonal antibodies processing |
title_fullStr | Integrated flow-through purification for therapeutic monoclonal antibodies processing |
title_full_unstemmed | Integrated flow-through purification for therapeutic monoclonal antibodies processing |
title_short | Integrated flow-through purification for therapeutic monoclonal antibodies processing |
title_sort | integrated flow-through purification for therapeutic monoclonal antibodies processing |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825194/ https://www.ncbi.nlm.nih.gov/pubmed/29271693 http://dx.doi.org/10.1080/19420862.2017.1417717 |
work_keys_str_mv | AT ichiharatakamitsu integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing AT itotakao integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing AT kurisuyasuhiko integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing AT galipeaukevin integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing AT gillespiechristopher integratedflowthroughpurificationfortherapeuticmonoclonalantibodiesprocessing |